Hematopoiesis News Volume 6.23 | Jun 16 2015

    0
    55

    Hematopoiesis News 6.23 June 16, 2015

    Hematopoiesis News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook   HN on Twitter

     
    TOP STORY
    Enhancing Hematopoietic Stem Cell Transplantation Efficacy by Mitigating Oxygen Shock
    By collecting and manipulating bone marrow and cord blood in native conditions of hypoxia, the authors demonstrated that brief exposure to ambient oxygen decreases recovery of long-term repopulating hematopoietic stem cells and increases progenitor cells, a phenomenon they term extraphysiologic oxygen shock/stress. [Cell] Abstract | Graphical Abstract
    Standardize Your CFU Assays With STEMvision for Automated CFU Assay Imaging and Analysis

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance
    Scientists demonstrated that T cell acute lymphoblastic leukemia (T-ALL) cells are in direct, stable contact with CXCL12-producing bone marrow stroma. Cxcl12 deletion from vascular endothelial, but not perivascular, cells impeded tumor growth, suggesting a vascular niche for T-ALL. [Cancer Cell]
    Abstract | Graphical Abstract | Press Release

    Hematopoietic Signaling Mechanism Revealed from a Stem/Progenitor Cell Cistrome
    A GATA-2-binding, Gata2 intronic cis-element (+9.5) required for hematopoietic stem cell genesis in mice is mutated in a human immunodeficiency syndrome. Because +9.5 is the only cis-element known to mediate stem cell genesis, researchers devised a strategy to identify functionally comparable enhancers genome-wide. [Mol Cell] Abstract

    Targeting Leukemia Stem Cells In Vivo with ANTAGOMIR-126 Nanoparticles in Acute Myeloid Leukemia
    The authors hypothesized that microRNA (miR)-126 contributes to ‘stemness’ and is a viable target for eliminating the leukemia stem cell (LSC) in acute myeloid leukemia (AML). They showed that miR-126 overexpression characterizes AML LSC-enriched cell subpopulations and contributes to LSC long-term maintenance and self-renewal. [Leukemia] Abstract

    Transdifferentiation of Erythroblasts to Megakaryocytes Using FLI1 and ERG Transcription Factors
    Several approaches to produce platelets from sources, such as haematopoietic stem cells and pluripotent stem cells, have been attempted but the system is extremely complicated, time-consuming and expensive. Researchers report a novel and simpler technology to obtain platelets using transdifferentiation of human bone marrow erythroblasts to megakaryocytes with overexpression of the FLI1 and ERG genes. [Thromb Haemost] Abstract

    Gaucher Disease-Induced Pluripotent Stem Cells Display Decreased Erythroid Potential and Aberrant Myelopoiesis
    Scientists differentiated induced pluripotent stem cells derived from patients with types 1, 2, and 3 Gaucher disease to CD34+/CD45+/CD43+/CD143+ hematopoietic progenitor cells and examined their developmental potential. [Stem Cells Transl Med] Abstract

    Comparative Long-term Effects of Interferon Alpha and Hydroxyurea on Human Hematopoietic Progenitor Cells
    Researchers compared bone marrow serially obtained from myeloproliferative neoplasms patients before and during pegylated interferon α treatment against marrow serially obtained from patients on hydroxyurea. [Exp Hematol] Abstract

    MYST2 Acetyltransferase Expression and Histone H4 Lysine Acetylation Are Suppressed in AML
    Scientists identified MYST2, a core histone acetyltransferase, to be suppressed in blast cells from acute myeloid leukemia (AML) patients compared to non-malignant hematopoietic progenitor cells. Loss of MYST2 accelerated leukemic growth and colony formation, while forced expression of MYST2 induced H4K5 acetylation and suppressed hematopoietic progenitor cell growth. [Exp Hematol] Abstract

    The Genetic Landscape of Hematopoietic Stem Cell Frequency in Mice
    Investigators used a genome-wide association study strategy with the hybrid mouse diversity panel to identify the genetic determinants of hematopoietic stem/progenitor cell frequency. [Stem Cell Reports]
    Full Article | Graphical Abstract

    CLINICAL RESEARCH

    High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning
    Researchers evaluated associations between graft T-cell doses and outcomes in 200 patients who underwent reduced-intensity conditioned allogeneic hematopoietic stem-cell transplantation with a peripheral blood stem-cell graft. [J Clin Oncol] Abstract | Press Release

    The Impact of Repeated Autologous Infusion of Hematopoietic Stem Cells in Patients with Liver Insufficiency
    Investigators assessed the clinical and biochemical effects of repeated stem cell infusion. Ninety patients with liver cirrhosis were randomized to receive either one session treatment or two sessions four months apart of autologous hematopoietic stem cells transplantation and a control group who received regular liver treatment. [Stem Cell Res Ther] Abstract | Full Article

    View Data: StemSpan™ SFEM II Serum-Free Medium

     
    REVIEWS
    Insights into Cell Ontogeny, Age and Acute Myeloid Leukemia
    Distinct biological processes and epigenetic modifications in pediatric and adult acute myeloid leukemia (AML) may mean that response to novel therapies may be different in children compared to adults with AML. The authors highlight both the commonalities and differences between pediatric and adult AML disease biology with respect to age. [Exp Hematol] Abstract

    Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

     
    SCIENCE NEWS
    Targeted Drug with Chemotherapy Combo Offers Longer Life to Patients with B-Cell Cancers
    Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma, an interim analysis has closed the international HELIOS Phase III clinical trial. [Press release from Mayo Clinic discussing research presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

    BioLineRx Presents Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment at European Hematology Association Conference
    BioLineRx Ltd. announced the presentation of positive safety and efficacy results for its lead oncology candidate, BL-8040, as a novel approach for the collection of stem cells from the peripheral blood circulation. [Press release from BioLineRx Ltd. discussing research presented at the 20th Annual Congress of the European Hematology Association, Vienna] Press Release

    From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

     
    INDUSTRY NEWS
    Baxter Ventures, Mayo Clinic and Velocity Pharmaceutical Development Announce the Formation of Vitesse Biologics, LLC, a Company Structured to Accelerate Therapeutic Innovation
    Baxter Ventures, Mayo Clinic and Velocity Pharmaceutical Development, LLC announced the formation of Vitesse Biologics, LLC. Vitesse is a unique collaboration model initiated by Baxter Ventures to focus on the development of antibody and protein-based therapeutics in the areas of immunology, hematology, and oncology. [Mayo Clinic] Press Release

    Sanford Consortium, Takeda Pharmaceutical Partner in $10-Million “Innovation Alliance”
    The Sanford Consortium for Regenerative Medicine and the Takeda Pharmaceutical Company Limited have agreed to establish a $10-million, five-year Innovation Alliance that would advance each organization’s research missions. [UC San Diego] Press Release

    Cord Blood Registry’s New Disease Registry Brings Data & Families Together to Advance Stem Cell Research
    Cord Blood Registry® announced the launch of CBR’s Family Health Registry, a unique registry designed to offer insight into common diseases and conditions affecting families and to bring patients, healthcare professionals and researchers together to expedite and facilitate research related to the discovery of stem cell treatments and potential cures. [Cord Blood Registry®] Press Release

    STEMCELL Technologies Named Company of the Year by BIOTECanada
    STEMCELL Technologies Inc. was presented with the Biotech Company of the Year award by BIOTECanada at this year’s BIO International Convention in Philadelphia. [BIOTECanada] Press Release

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW 16th International Workshop on Chronic Lymphocytic Leukemia
    September 7-9, 2015
    Sydney, Australia

    Visit our events page to see a complete list of events in the hematopoiesis community.

     
    JOB OPPORTUNITIES
    NEW Postdoctoral Position – Hematopoietic Stem Cell and Hematologic Malignancy (University of Kentucky College of Medicine)

    Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

    Research Associate – Cell Separation (STEMCELL Technologies Inc.)

    Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Harvard Medical School)

    Postdoctoral Fellow – Cell Fate Decisions in Normal and Malignant Blood Stem Cells (University of Cambridge)

    Head of Stem Cells Immunotherapies Service Lab (NHS Blood and Transplant)

    Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

    Postdoctoral Fellow – Immune Tolerance (Stanford University)

    Postdoctoral Position – Epigenetic Regulation of Hematopoiesis and Leukemia (Karolinska Institute)

    Postdoctoral Researcher – Hematopoietic Stem Cell Physiology and Pathophysiology (International Research Center for Medical Sciences)

    Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)


    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Hematopoiesis News: Archives | Events | Contact Us